I am a
Home I AM A Search Login

Papers of the Week

2019 Oct

Appl Health Econ Health Policy



Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.


McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, Varghese L, Curran D
Appl Health Econ Health Policy. 2019 Oct; 17(5):723-732.
PMID: 31250218.


In Canada, incidences of herpes zoster (HZ) and postherpetic neuralgia (PHN) are increasing, posing a significant burden on the healthcare system. This study aimed to determine the public health impact and cost effectiveness of an adjuvanted recombinant zoster vaccine (RZV) compared to no vaccination and to the live attenuated vaccine (ZVL) in Canadians aged 60 years and older.